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Layman’s summary
The cornea is a delicate structure found in the outermost layer of the eye. It is transparent,
dome-shaped and plays a critical role in being able to see correctly. Each year, the economic
burden of eye diseases and vision loss is estimated to be 139 billion dollars in the US.
Furthermore, the market size of eye-related pharmaceuticals was approximately 12 billion
dollars in 2010 in the US alone. However, despite these astounding numbers, developing new
drugs for eye diseases has been difficult, with few drugs being developed each year. There are a
lot of different factors influencing this disparity between money spent and drugs developed, one
of them being a lack of understanding of the functioning of the cornea in its healthy and
diseased state. Although the cornea is transparent and might seem to lack structure, it is a highly
organized and complex tissue. In particular, innervation, i.e. the supply of nerves to the cornea,
is critical for its function.
Biological models can be used to study the cornea and discover potential new drug targets.
Currently, the most popular way to evaluate drug toxicity is through a ‘Draize’ test. In this test a
substance is applied to the eye of a live rabbit, and the other eye is used as a control to see the
difference. However, ethical concerns with using live animals, lack of reproducibility and the
interspecies difference between humans and rabbits show that this test is not optimal.
Development of in vitro, meaning in a controllable environment that’s outside a living
organism, 3-dimensional models can avoid these limitations.
Herein, we describe a novel 3D in vitro model for the cornea. We use novel fabrication
techniques to modify common biomaterials to create a corneal model that includes innervation.
We found that applying an electric current to collagen results in an optimal material for
mimicking the cornea in a model. Additionally, we 3D printed live neuronal cells within another
biomaterial and showed their survival. To guide the direction of the growth of neuron-like cells
we fabricated very microparticles with neural growth factor inside. These were combined with
collagen and the 3D printed neuron-like cells to create an overall model for the cornea with
innervation. The current model requires further optimizing in regards to increasing innervation,
although the first steps to producing a novel model have been taken.
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Abstract
Visual impairment due to corneal disease is a global health concern with few FDA-approved
pharmaceuticals being developed. In the cornea, the interactions between the various cell types
present are essential for its functioning. In particular, innervation through sensory nerves is
crucial for optimal functioning of this tissue. However, the mechanisms underlying these
interactions are poorly understood, and representative 3D innervated in vitro cornea models
could be used as systems to model the native situation.
Therefore, an innervated model of the cornea is proposed and initiated. Electrocompacted
collagen constructs serve as a basis for mimicking the cornea, and its mechanical, optical, and
degradative properties are shown to be favorable. Furthermore, three dimensional extrusionbased printing has been employed to print methacrylated gelatin, and this scaffold was shown to
support neuronal cell survival (83.4% viability 1 day after printing). A sustained release of
neural growth factor to induce differentiation was established through incorporation of growthfactor loaded microparticles within the electrocompacted collagen. Additionally, the bioactivity
was confirmed through an in vitro PC12 cell assay. The two biomaterials have been interfaced
to fabricate a model to guide neuronal innervation. The current model shows potential in
mimicking the complex structure of the cornea, but some optimization is required for neurite
outgrowth. In the future, a viable in vitro corneal model could be used to provide fundamental
insight into the process of corneal innervation and corneal diseases, as well as pre-clinical
toxicity testing of new ocular drugs.

6

Acknowledgments
I wish to express my sincere gratitude to my co-supervisors Dr. Xiao Liu and Dr. Stephen
Beirne for their assistance during the entire project. I specifically would like to thank Xiao for
allowing me to, at times, work independently, while, at other times, keeping me on the right
track through expert guidance. I would additionally like to extend my gratitude to my clinical
mentor, Dr. Gerard Sutton, for the support and advice during the monthly updates. Lastly, I
would like to thank Prof. Dr. Gordon Wallace and Prof. Dr. Jos Malda for the opportunity to
work within ACES and IPRI through the exchange program set up via the Biofabrication
master’s degree.
Additionally, I also worked on a review paper “Advanced fabrication approaches to controlled
delivery systems for epilepsy treatment”, currently under review, the abstract of which is added
at the end of this report as additional information. For this, I would like to thank my co-authors
Marius Berthel, Dr. Zhilian Yue, and Dr. Mark Cook and my previously mentioned supervisors.

7

Certification

I, Gilles van Tienderen, declare that this thesis submitted in fulfilment of the requirements
for the conferral of the degree Biofabrication, from the University of Wollongong, is wholly
my own work unless otherwise referenced or acknowledged. This document has not been
submitted for qualifications at any other academic institution.

Gilles Sebastiaan van Tienderen
27-6-2018

8

List of Names or Abbreviations
3D - Three-dimensional
ECM - Extracellular matrix
NGF – Neural growth factor
BDNF – Brain-derived neurotrophic factor
NT-3 – neurotrophin-3
GDNF – Glial cell line-derived neurotrophic factor
ATP – Adenosine triphosphate
RGD – Arg-Gly-Asp
GelMA – gelatin methacrylate
EC – electrocompaction
ECC – electrocompacted collagen
ITO - Indium tin oxide
PBS – Phosphate-buffer saline
DMSO – Dimethyl sulfoxide
UV – Iltraviolet
EM – Expansion medium
DM – Differentiation medium
DMEM – Dulbecco’s Modified Eagle Medium
PCL - Polycaprolactone
LAP - Lithium phenyl-2,4,6-trimethylbenzoylphosphinate
PLGA – poly(lactic-co-glycolic acid)
DAPI - 4′,6-diamidino-2-phenylindole
DCM - Dichloromethane
PVA – Poly(vinyl alcohol)
ELISA – Enzyme-linked immunosorbent assay
FITC-BSA – Fluorescein isothiocyanate labelled bovine serum albumin
SEM – Scanning electron microscopy
MP(s)- Microparticle(s)

9

List of Tables, Figures and Illustrations
Figure 1: The anatomy of the cornea and eye. Adapted from Huhtala et al.114

Figure 2: A schematic depiction of the distribution of human nerves in the cornea.
Unmyelinated nerves (blue) are made up out of straight (red) and beaded (green) fibers.
Obtained from Muller et al.113
Figure 3: Development of cornea tissue models. Obtained from Huhtala et al.49

Figure 4: Mechanisms of electrocompaction of an aligned collagen thread. Adapted from
Younesi et al.77

Figure 5: Electrocompaction of collagen. Pre-crosslinked electrocompacted collagen (A). After
Riboflavin crosslinking (B). Representative graph of current over time for electrocompaction of
collagen type I

Figure 6: Mechanical assessment of riboflavin crosslinked ECC. A typical stress-strain curve
displayed by tensile testing ECC (A). Tensile modulus (B). Ultimate stress and ultimate strain
(C). All values are displayed in kPa and %. Error bars represent std. error of mean (SEM). (n =
3)

Figure 7: Light Transmission spectra from collagen and GelMA samples over the visible light
spectrum. The light transmission spectra of the biomaterials was measured continously between
390 nm and 800 nm and compared to a baseline of DI H2O. The average of n = 3 was taken for
all samples. ECC = electro compacted collagen post-crosslinking, gelMA = methacrylated
gelatin

Figure 8: Passive degradation assessment of electrocompacted collagen samples by means of
dry polymer weight. Data is presented in mean ± SD (n = 2).

Figure 9: Optimizing differentiation density of PC12 cells on plastic culture substrate. Arrows
indicate extensive neurite outgrowth in the differentiation conditions. Scale bar = 200 um. DM
= Differentiation medium, CM = Culture medium

10

Figure 10: Microscopic analysis of printed and seeded 10% w/v GelMA scaffolds 1 day post
printing. Printed scaffold (A), (B). Seeded scaffold (C), (D). scale bars = 200 um

Figure 11: Live/dead staining of PC12 cells bioprinted within 10% w/v GelMA 1 day post
printing. Live (left), dead (middle), and merged (right). Calcein/PI was used to stain the live
(green) and dead (red) cells, respectively. Scale bar = 200 um

Figure 12: The effect of printing and seeding PC12 cells on their metabolic activity for the
duration of 7 days measured via PrestoBlue.

Figure 13: Beta-III tubulin staining of PC12 cells printed within 10% w/v GelMA after 12 days.
Neurite outgrowth can be seen going along the printed scaffold. Beta-III Tubulin is displayed in
red and DAPI staining is displayed in blue. Scale bars = 200 um

Figure 14: Representative fluorescent microscopy pictures of w/o/w PLGA microparticles in
aqueous solution at low (left) and high (right) magnification showing the spherical morphology
and successful encapsulation of FITC-BSA within the microparticles. Scale bars = 200 um

Figure 15: Size distribution by fraction of growth factor loaded PLGA microparticles sized
using ImageJ software. 0.5% PVA, 10% PLGA (A). 1% PVA, 20% PLGA (B). 0.5% PVA,
20% PLGA (C). 1% PVA, 25% PLGA (D).

Figure 16: Release curve showing the absolute cumulative release of neural growth factor from
the 0.5% PVA 20% PLGA microparticles over a period of 8 days. Growth factor release was
quantified using ELISA through generating a standard curve (top left) and fitting the unknown
data points after subtracting background absorbance. All measurements were taken in triplicate.

Figure 17: Optical microscopic pictures displayed the behavior of the PC12 cells after culturing
with or without NGF:MPs and empty control microparticles for the duration of 9 days. Black
arrows indicate morphological changes and neurite outgrowth. Black dots are microparticles
present in the medium. Scale bars = 200 um

Figure 18: Representative scanning electron microscopy (SEM) images of electrocompacted
collagen without microparticles (A), with 5 mg/mL microparticles (B) and 10 mg/mL
microparticles (C, D). (E) shows the disruption of ECC due to microparticle incorporation.
Scale bars as indicated.

11

Figure 19: Live/Dead stainings of PC12 cells within 10% w/v GelMA. (A) middle of scaffold
after electrocompaction of collagen. (B) Top of scaffold after electrocompaction of collagen.
(C) Scaffold after undergoing the procedure without applying current. (D) control scaffold.
Calcein/PI was used to stain alive (green) and dead (red) cells, respectively. Scale bars = 200
um
Figure 20: Live/Dead staining’s of PC12 cells within 10% w/v GelMA after optimizing the
effect of printing on cell viability after 1 day (left) and 7 days (right). Scale bars = 200 um

Figure 21: Beta-III tubulin staining of PC12 cells within the interfaced innervated model. Cells
outgrow few neurites when NGF is dispersed within the medium (A, B). No sign of neurite
outgrowth present in the interfaced innervated model of ECC:MP with 10% w/v GelMA (C, D).
Neurite outgrowth can be seen extensively when seeded on top of 10% w/v GelMA (E, F), or
when cultured with NGF:MP:ECC (G, H) . Beta-III Tubulin is displayed in red and DAPI
staining is displayed in blue. Scale bars = 200 um

Table 1: Average sizes of the microparticles produced with different concentrations of PVA and
PLGA. All values are represented as mean with std. error of mean

12

Chapter 1: Introduction
A high-quality model of the cornea can provide new knowledge and insight on corneal
functioning, both in regards to physiology and pathology. To develop a viable in vitro model of
the cornea, it is critical to have a thorough understanding of the native cornea and its function in
its healthy and diseased state. In this first chapter we describe the anatomy and structure of the
cornea, with a more in depth look at innervation. Current materials for corneal bioengineering
are discussed with their potential for in vitro models. Novel advanced biofabrication techniques
are introduced, after which the aims of this research project are described.

1.1 Corneal structure, anatomy and functioning
The cornea is the outermost part of the human eye and consists of three main distinct layers: the
epithelium, stroma and endothelium (Fig. 1). These three layers are separated by two acellular
interfaces called the Bowman’s layer and Descement’s membrane.1 The cornea is a transparent,
avascular, connective tissue and is responsible for about 60% of the eye’s refractive power.2
Furthermore, it serves an important function as a protective barrier, both mechanically and
pathologically (against infections). The thickness of the human cornea is around 500-600 um in
the center and 600-800 um in the periphery, with a vertical and horizontal diameter of
approximately 11-13 mm.3,4 The cornea consists primarily of collagen fibers and some smaller
proteoglycans, predominantly keratin sulfate and glycosaminoglycan.5
The corneal epithelium is the layer of the cornea that is directly in contact with the external
environment, and makes up around 10% of the total corneal thickness.6 Its main component is
about 4-5 layers of stratified epithelial cells, which are held together by tight junctions.7 The
primary functions of the epithelium, together with the tear film, are to serve as a barrier against
pathogen invasion, prevent loss of fluid and permit coherent refraction of light that enters the
cornea.8,9,10 The epithelium of the cornea is one of the most abundantly innervated tissues in the
body, with free sensory and nociceptive nerve endings spread all along the outer surface.11
The corneal stroma constitutes 85-90% of the corneal thickness and is built up from aligned
layers of collagen fibrils, also termed lamellae, and keratocytes.12 Keratocytes are interspersed
between the lamellae and provide the extracellular matrix (ECM) components of the stroma.13
The collagen fibrils mainly consist of type I, V and VI collagen, with some of the previously
mentioned proteoglycans interspacing the lamellae to allow for transparency and regulation of
corneal hydration.5,14 These organized collagen bundles provide the cornea with proper
mechanical support, the right biophysical properties for maintenance of transparency as well as
biochemical cues for keratocyte cell signalling.15–17 In the healthy native cornea, transmittance,
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as a surrogate for transparency, thresholds are around 80% at 380nm and more than 90%
between 500 nm and 1300 nm. 17 It is clear that for any in vitro model to be viable it is critical to
closely mimic this unique structure present in the cornea.
The corneal endothelial layer is a monolayer of endothelial cells that covers the posterior
corneal surface.18 Under healthy circumstances, the corneal endothelial cells do not proliferate.
Their main function is to provide a metabolic active Na+/K+ pump to maintain healthy hydration
levels in the corneal stroma by moving ions around and thereby using osmosis for water
removal.19 Correct hydration levels have been shown to be a necessity for transparency of the
cornea.20

1.2 Corneal innervation
Corneal innervation is a component of the cornea that is interwoven in the stromal and epithelial
layers of the cornea and is vital to the functioning of the cornea as a whole. The cornea is the
most peripherally innervated surface of the human body.21 The innervation originates from the
trigeminal ganglion cells, which branch to form the limbal plexus, which in turn gives rise to
stromal nerve trunks that enter the periphery of the corneal stroma.22,23 The nerves are
directionally orientated parallel to the lamellae in the cornea and as they move more
superficially, they branch into various smaller neurites.24 The growth and guidance of these
nerves during the development of the cornea is modulated by various growth factors. Nerve
growth factor (NGF) has been uncovered as one of the most important growth factors for nerve
survival and regeneration, as well as axonal outgrowth, branching and sprouting.25 Other
important factors include brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and
glial cell line-derived neurotropic factor (GDNF).26,27 The interplay between these various

Figure 1: The anatomy of the cornea and eye. Adapted from Huhtala et al.114
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growth factors forms the basis for the extensive innervation present in the cornea. Furthermore,
mimicking the innervation as seen in vivo will rely on the ability of the corneal model to create a
sustained release of NGF and/or other neuronal related growth factors.
The corneal nerves provide a platform for sensing, both mechanically and thermally, in order to
maintain the overall health of the cornea. The particularly high density and unique exposure of
the free nerve endings make the cornea (hyper)sensitive to noxious stimuli.28 The nerves
function by reaching the threshold of the receptors present, resulting in action potentials being
relayed to the central nervous system. Among others, the innervation of the cornea plays an
important role in wound healing and regeneration, the tear reflex and tear production and
secretion.29–31 These functions are regulated through a complex system of secretion and sensing
of a multitude of neurotransmitters and peptides. A more extensive review on the various factors
involved can be found in a recent review by Shaheen et al.25 It has been established that the
dysfunctioning of corneal nerves is frequently associated with corneal diseases, ultimately
leading to a reduction in vision.32 Despite this, the exact role of neuronal innervation, and the
cellular mechanisms behind it, in the healthy and diseased state of the cornea are not fully
elucidated.33 This is partly due to the highly complex biochemical and anatomical pathways of
corneal diseases that provide a hurdle for examination in vivo.34,35 As a consequence, despite the
relative high prevalence of corneal diseases, there are few therapeutic interventions available for
corneal diseases.25 More recently, research has delved into the use of a wide variety of
biomaterials as building blocks for creating corneal tissue through bioengineering strategies.

1.3 Current cornea models
As may be evident, the primary functions of the cornea dictate important design considerations
that a corneal tissue model will need to satisfy depending on the application. In vitro models can
range from simple monolayered structures to full-thickness corneal substitutes. One of the
earliest and simplest human models featured a layer of human primary epithelial cells cultured
for toxicology testing.36 More recent advances in human primary epithelial cells primarily
focused on optimizing the in vitro culturing conditions with varying toxicity applications. For
example, testing natural tear substitutes using cellular ATP as the parameter for defining
toxicity showed potential therapeutic benefit of isotonic saliva and serum compared to
pharmaceutical substitutes.37 Various other mono-layered cultures of relevant corneal cell types
have been published and some are currently commercially available.38,39 Mostly, these rather
elementary models may provide insight for immediate surface irritancy testing.40 However,
these models of the corneal epithelium layer do not accurately represent the multi-layered
structure of the cornea as found in vivo (fig. 2). Additionally, they lack all interactions between
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different cell types present in the cornea. For applications focusing solely on the epithelial or
endothelial component of the cornea, one can envision the lack of a supporting biomaterial not
being crucial, as the in vivo situation mostly consists of a densely packed layer of cells.
However, to mimic the stroma of the cornea, or a combination of multiple layers, it is of utmost
importance to choose a suitable material as well as the correct cell source. A wide variety of
materials have been studied with the goal of exploring fundamental research on cornea and
finding alternatives for current corneal dysfunction treatments. Both natural and synthetic
polymers have been studied, including silk, gelatin, chitosan, collagen and other synthetic
polymers. As a complete overview of all usable materials is beyond the scope of this thesis, and
has been done exhaustively by Chen et al.41 , the focus will be primarily on certain
characteristics that are needed to allow for optimal corneal tissue mimicking and the
biomaterials that can provide these characteristics within the scope of in vitro models. To note,
in principle, complex 3D tissue models should be proficient at mimicking the human cornea,
compared to simple 2D cell culture models (fig. 3). However, so far the difference has not been
apparent.42 Surprisingly little research has been published on recapitulating the cornea in a 3D
model. Thus, whether this phenomenon (2D =3D models in cornea) is due to the lack of
research on 3D corneal models remains to be seen. The need for increased attention for reliable
models is shown by the clinical need for these advanced models (see Box 1).

Figure 2: A schematic depiction of the distribution of human nerves in the cornea.
Unmyelinated nerves (blue) are made up out of straight (red) and beaded (green) fibers.
Obtained from Muller et al.113
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Box 1. Clinical need for in vitro cornea models
The ophthalmic drugs market has been increasing in value continuously from 12 billion in 2010 to
approximately 52.4 billion in 2017.99 This has resulted in more investments from the large pharma
companies such as Merck and Pfizer. Although the pharmaceutical market has been growing
heavily, the amount of drugs approved by the FDA has decreased in recent years.99 Although
there are a variety of reasons contributing to this, an important factor remains the lack of
fundamental understanding of corneal functioning together with difficulties in developing reliable
pre-clinical testing methods.100,101
The current gold standard for evaluating drug toxicity is the in vivo Draize test performed on
rabbit corneas.102 In this test, the substance is applied to one eye of the rabbit, while the other
eye is used as a control. Besides ethical concerns, there is a lack of reproducibility and the
interspecies differences result in inconsistencies with human responses.103,104 As an alternative, ex
vivo cornea models have been developed by isolating animal corneas.105,106 Nevertheless, these
models share similar limitations to the Draize test. On top of that, the pain response cannot be
established as the excision of the cornea results in irreparable nerve damage.107 These limitations
can be avoided by the development of new in vitro models. These models minimize ethical
concerns, are more cost-effective, able to utilize human cells, and can provide higher throughput
analysis for drug testing and screening.108 Three-dimensional models have first been developed
using a variety of animal cell sources, including bovine, mouse and pig.109–111 Additionally, various
in vitro models solely using (immortalized) human corneal cells have also been published.40,57,112

Figure 3: Development of cornea tissue models. Obtained from Huhtala et al.49
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1.4 Biomaterials for corneal model fabrication
1.4.1 Gelatin
Gelatin is a natural polymer derived from the (partial) hydrolysis of collagen. Due to its
biocompatibility, biodegradability and inexpensiveness it has been widely used in a range of
tissue engineering strategies, including bone, skin and cornea. Gelatin has inherent cell binding
motifs, most importantly Arg-Gly-Asp (RGD), allowing for relatively good cell adherence and
spreading. This has been shown through the seeding of human endothelial corneal cells and
precursor fibroblasts.43,44 Due to its relatively close proximity in structure to collagen, gelatin is
a potential biomaterial well-suited for corneal applications. However, modifications are usually
required to give it proper structural fidelity.45 Gelatin methacrylate (GelMA) is a popular gelatin
derivative that is modified so that covalent cross-linking can occur through photo-initiated
radical polymerization.46 This semi-synthetic semi-natural material keeps the advantageous cell
binding motifs of gelatin while obtaining the tunable physical characteristics usually only seen
in synthetic materials. Its variability in chemical and mechanical properties due to the wide
variety of crosslinkers that are compatible with gelatin shows potential for corneal in vitro
models, however, similar mechanical properties to native cornea have not been achieved to this
date.47 GelMA has been widely used as a tunable scaffold for a variety of cell types, however
little research has been done on combining it with corneal relevant cell types and, to our
knowledge, no corneal 3D models have been fabricated using gelatin as a major component.

1.4.2 Silk
Silk is a naturally-sourced biomaterial that has been utilized as a substrate for corneal
applications due to its natural optical clarity, mechanical robustness and tunable chemical
modifications.48 Unmodified silk membranes do not contain RGD motifs, and although they
provide similar cell attachment properties as seen on plastic culture substrates, RGD-containing
materials (i.e. gelatin) show increased cell responses. Coupling of a RGD motif to the silk film
provided better cell attachment, as well as increased expression of collagen type I and IV, both
abundant in native cornea.49 An apparent advantage of silk over gelatin is the potential of
patterning, which has been shown to be critical in the behavior of corneal cells.50 For example,
the topography of silk, depending on the depth and width of grooves introduced into the
substrate, influenced the attachment, proliferation and migration of human corneal epithelial
cells.50,51 Additionally, modified silk films can obtain similar elastic moduli to the cornea,
although these elastic moduli have only been shown by using water vapor annealing as a
crosslinking method.52 Interestingly, the combination of this crosslinking technique and
biomaterial has not been further explored for corneal tissue engineering. Notably, the most
recent development in a full-scale corneal equivalent model used silk as a basis for the culture
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of human corneal stromal stem cells, human corneal epithelial cells and DRG neurons.53 This is
the first reported model that was able to successfully integrate all three cell types within a single
model. Furthermore, an air-liquid interface was included to mimic the native corneal interface,
and the addition of innervation showed an improvement in viability of both corneal cell types.
Importantly, to guide neuronal innervation NGF was patterned within the silk film and loaded
within the hydrogel. Although this corneal model is the most sophisticated model produced so
far, some limitations have to be taken into consideration. The base biomaterial is mismatched
with native cornea, and, more importantly, the unique structure of the cornea, with approx. 200
lamellae layered together to form a thickness of 500 um, is not represented well by the few
layers of silk film used in this model. Lastly, the mechanical strength/elastic moduli of the
construct is not reported.

1.4.3 Collagen
As mentioned previously, collagen is the most abundant protein in the human cornea and for
that reason an ideal biomaterial for use in corneal tissue engineering. Collagen is available
through a wide variety of sources, including animal-derived and recombinant, as well as from a
variety of tissues (tail, skin, etc.). The source and tissue of origin of collagen can have a large
effect on its properties and performance, hence choosing the right collagen to utilize is
paramount to its success. Research has established the effect of particular sources of collagen on
important characteristics (tensile strength, denaturation temperate, light transmittance and fibril
alignment) that are of particular relevance for corneal applications.54 Hydrogels based on
collagen are biodegradable and biocompatible with a variety of corneal-related cell types,
including limbal epithelial cells and primary stromal fibroblasts.55,56 In regards to cellular
response and interaction, collagen is a biomaterial that is best suited for corneal applications,
without exception. However, unmodified collagen is compliant and has low mechanical
stiffness, making it unsuited for corneal tissue engineering. Naturally, much of the research on
collagen for corneal applications has been focused on modifying collagen, chemically or
physically, to increase its mechanical performance. Crosslinking is a common method of
increasing the strength of collagen hydrogels, primarily collagen type I. Crosslinking usually
refers to the process of chemically joining two molecules through covalent bonding, commonly
through cleaving and/or attaching chemical groups to the original substrate. It is important to
take into consideration that with chemical crosslinking some agents have toxic effects (through
e.g. the generation of toxic side-products) on cells, including a variety of corneal cell types.
Thus, research has been focused on identifying cytocompatible cross-linking agents, such as
riboflavin, genipin, and EDC-NHS.. 57 Interestingly, Duan et al. found that chemical
crosslinking resulted in collagen hydrogels that not only had enhanced mechanical properties,
but also increased optical transparency.58 The most common agent used is EDC-NHS. This
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method strengthens the hydrogel by crosslinking carboxylic acids with primary amines.59
However, the strength and stiffness currently achieved with this agent was at least one order of
magnitude lower than native cornea. Furthermore, it is important to note that although the
transparency of the biomaterial did increase, the collagen fibers present had a lack of
organization and direction, unlike the structural assembly of collagen fibers found in native
cornea.60
A major discrepancy between collagen used in vitro and natural collagen containing tissues in
the body is density of the collagen molecules because of their compaction. In the body collagen
structures can be as dense as 250-400 mg/mL, while for hydrogels this is usually contained with
the range of 1-10 mg/mL. Collagen is an ampholytic molecule by nature, which means that it
can obtain different charges at different pH levels (-0.8 coulombs at pH of 3, +0.8 coulombs at
pH 11).61 These characteristics resulted in the development of an electrochemical compaction
method for collagen.61 Herein, the collagen molecules closely pack together at the isoelectric
point, which is the point where the net charge of the collagen molecules is zero. Building on
this, Kishore et al. showed the potential of electrocompacted collagen, with EDC-NHS
crosslinking, as a basis for corneal applications (fig. 4).62

Collagen has been used previously for in vitro corneal model applications. Ahearne et al. used a
basic collagen-based in vitro model of the cornea, specifically focusing on wound healing, to
monitor the effect of collagen and cell concentration on cell-matrix interactions.63 The relatively
novel realization of the importance of corneal innervation, has led research to be focused on
tissue models that include a neuronal aspect. Suuronen et al. used chicken-derived dorsal root
ganglion (DRG) neurons to innervate a model containing corneal endothelium and stroma.64 The
neurons and corneal cells were cultured in a collagen hydrogel, and the addition of innervation
resulted in an increased proliferation of the endothelial cells. Nevertheless, the density of nerve

Figure 4: Mechanisms of electrocompaction of an aligned collagen thread. Adapted from
Younesi et al.77
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endings were significantly lower compared to native cornea, the collagen hydrogel had low
mechanical stiffness and the epithelial layer was not included in the model. Another 3D corneal
model, consisting of ND7/23 sensory neurons and a human corneal cell line interestingly
showed that the incorporation of the neurons did not influence the barrier function of the corneal
epithelial cells. Additionally, although not yet explored in relation to corneal models, PC12 cells
have been used extensively as models for neuronal innervation and neurosecretion.65,66 In all, the
use of conventional collagen hydrogels in corneal tissue engineering has been highly prevalent,
however the issue of mechanical properties is a recurring problem for these types of
constructs.67

1.5 Biofabrication techniques for corneal applications
A particular field of interest for innovation within the scope of corneal tissue engineering is the
convergence of cell biology and advanced fabrication methods, also referred to as
biofabrication. One novel fabrication technique, the previously mentioned electrocompaction
technique, provides a solution to address the problem of low mechanical stiffness.

1.5.1 3D Bioprinting
In the field of biofabrication, 3D bioprinting is a technique that has gained significant attention
for tissue engineering applications due to its ability to create a hierarchical assembly of
biological structures using 3D printing technology. Herein, optimal nutrient diffusion and
spatio-temporal localization of cells can be achieved through deposition of bio-inks in a
predefined pattern. A variety of 3D bioprinting techniques have been developed and
investigated, although seldom for corneal applications.
Using laser-assisted bioprinting and corneal limbal stem cells Sorkio et al. were able to create a
layered structure mimicking the stroma. In short, laser-assisted bioprinting uses a pulsed laser to
produce a jet of solution which can be deposited onto a substrate.68 With this technique, high
resolution and high cell density prints can be produced. The stem cells were situated inside a
bioink consisting of recombinant laminin and collagen type I, specifically adapted to the laserbased printing setup. Microstructure analysis, extensive protein expression analysis and cell
viability results showed the potential of using laser-assisted bioprinting for corneal
applications.68 Very recently, Isaacson et al. used a 3D digital human corneal model to bioprint
corneal keratocytes to create a biosynthetic corneal structure using extrusion-based 3D printing.
This printing method employs a pneumatic-, mechanical- or solenoid-based system to deposit
viscous and semi-liquid materials from a nozzle in a layer-by-layer fashion. The keratocytes
were printed within a collagen/alginate bioink, and showed relatively high viability post
printing. However, no other biological properties were investigated, such as differentiation or
cell attachment properties. Furthermore, no in vitro characterization was done on the printed
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structures (e.g. mechanical strength, transparency, stability, etc.). Lastly, the bioink had very
low fidelity during the printing process, and a commercially available support structure was
required to maintain shape and structure.69 For neuronal innervation, similar to other cellular
processes, it is important that nutrient diffusion is sufficient to sustain proliferation and
differentiation of the cells. Additionally, while 2D neural cell cultures have their place in
studying certain aspects of neural development, 3D cultures are able to more accurately
represent the in vivo microenvironment of neural tissues.114 Particularly, 3D bioprinting of
neuronal constructs allows for defined control over the neuronal microenvironment, both
through the bioink and potentially by addition of other (growth) factors to the bioink. The
spatiotemporal patterning of the cells and growth factors allows for precise control over
neuronal outgrowth, and thus can be used to better recapitulate the native environment.115 To
this regard, extrusion-based bioprinting could be used for corneal innervation applications.
All innervated corneal models previously described shared the characteristic of NGF-guided
neurite extension, whether through stamped silk films, addition within a collagen hydrogel or
otherwise. One avenue which has not been previously explored in relation to corneal models is
the fabrication of microparticles. Growth factor-loaded microparticles have been used for a
variety of sustained release applications, including in vivo intracerebral implantation and bone
tissue regeneration.70,71 This method of creating a relatively long-term release of neural growth
factor could hold potential for applications within 3D in vitro corneal models.
All in all, 3D cornea in vitro models hold potential to complement currently employed models
for a variety of applications, ranging from basic fundamental research to drug toxicity testing.
However, the small volume of research currently published on these models show the need for
further investigations. As it stands, the current generation of in vitro 3D corneal models lack one
or more of these features:
(i)

full representation of the multi-layered cornea structure, particularly stroma.

(ii)

The incorporation and interaction of the different cell types present in the cornea
(nerves/epithelial/endothelial/keratocytes).

(iii)

A sustained function for a longer period of time (>7 days required for basic in vitro
testing and sufficient neurite outgrowth)

(iv)

similar mechanical properties to native cornea, wich have a Young’s modulus of
approx. 290 kPa. 80
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1.6 Aims
To address these issues, the ultimate aim is to create an in vitro 3D corneal tissue model that
represents corneal tissue in regards to the distinctive layers present in vivo, containing multiple
cell types and allowing for guidance of neurite outgrowth. For this project, the focus will be on
creating a platform for neuronal survival and differentiation. The neuronal cell source utilized
will be PC12 cells. For this reason, a sustained release of neural growth factor has to be
achieved to create a guided innervation model. Additionally, an emphasis will be on
investigating electrocompaction of collagen as a competent biomaterial to mimic the native
cornea.
The specific aims of this project are:
(i) Investigate electrocompacted collagen as an optimal material for 3D in vitro corneal models,
(ii) Perform extrusion-based bioprinting with GelMA to provide a basis for neuronal cell
survival,
(iii) Establish a method of sustained release of neural growth factor through fabrication of
microparticles,
(iv) Create an innervated model of the cornea through interfacing (i), (ii), and (iii) in a single
construct.
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Chapter 2: Materials and Methods
2.1 Electrocompacted Collagen production
2.1.1 Electrocompaction (EC) chamber fabrication
The EC chamber consists of three main components, a cathode, an anode and a spacer (see
suppl. Fig. 1). The top part is ITO-coated glass (30x30 mm), cut to dimensions with a glass
cutter. The ITO coating enables the glass to be conductive, thus acting as the cathode. The
bottom part is a stainless steel plate (35x35 mm). The stainless steel is conductive and acts as
the anode. A small copper strip is attached to both the ITO-coated glass and stainless steel plate
to allow for crocodile clips to be attached. In the middle a non-conductive spacer is required to
prevent short circuiting. The spacer is made out of standard acrylic, cut to custom dimensions
with a laser cutter (Universal Laser Systems GmbH, Vienna, Austria). The height of the
chamber can be adjusted by using multiple layers of acrylic. The complete set-up is held
together with clamps to prevent leakage (suppl. fig. 1). The process of electrocompaction can
take place due to the previously mentioned ampholytic nature of collagen (fig. 3).

2.1.2 Fabrication of EC collagen sheets
6 mg/ml Type-1 bovine collagen solution (Nutragen, Advanced BioMatrix, CA, USA) was
diluted with sterile deionized H2O to 3 mg/ml. Afterwards, it was dialyzed against deionized
water for 24-48h at 4°C, refreshing the water a total of 4-6 times. After dialysis the collagen
solution is injected into the EC chamber via a 1 mL syringe and needle. By using the ITOcoated glass as an anode and the stainless steel plate as a cathode a constant voltage (5v, 600 s,
e^-003 sensitivity) is applied to the collagen solution through the use of an electrochemical
workstation (CH Instruments, Texas, USA). The electric current results in a formation of a pH
gradient which, due to the amphoteric nature of collagen, causes the collagen molecules to
migrate and align close to the isoelectric point. After the electrocompaction process is
completed the collagen sheet can be harvested from the anode. To promote fibril formation after
the process of electrocompaction, the collagen sheet is incubated in 10x PBS at 37 °C for 3h.

2.1.3 Crosslinking of EC collagen sheets
To enhance the mechanical properties and stability of the EC collagen crosslinking occurred
post-electrocompaction. 10 mM riboflavin was dissolved in 10 mL DMSO, after which it was
added to 90 mL H2O and used as a crosslinking agent. After incubation in PBS the collagen
sheets were transferred to the riboflavin solution and re-incubated for 4h at 37 °C. Hereafter,
365 nm UV-light with a 100 W lamp (90% intensity) was applied for 120s using a UV LED
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curing system (Model no. S1000-1B, Lumen Dynamics, Mississauga, Canada). To remove the
residual riboflavin crosslinking solution the collagen sheet was incubated in PBS for 5h. The
final incubation in PBS allows the yellow color from the riboflavin solution to be removed from
the collagen sheet.

2.1.4 Mechanical assessment
To assess the mechanical properties of ECC tensile testing was performed using a Shimadzu EZ
mechanical tester with a 10N sensor attached. After calibration, tensile tests were performed on
ECC with fixed dimensions (15 x 5 mm) (n = 3). In short, samples were attached to paper tabs
to allow for clamping without destruction of the material. The thickness of the ECC was
measured with a microscope and three values were taken and averaged. Uniaxial tensile loading
was performed until failure with a strain rate of 1 mm/min. Load vs displacement data was used
to determine the stress strain curves and in turn calculate the ultimate stress, ultimate strain,
young’s modulus and tensile modulus. Tensile strength is classically defined as the value of the
maximum stress that a material can handle. Young’s modulus is defined as the slope at the
beginning of the curve . See Suppl. Fig. 2 for a graphical representation.

2.1.5 In vitro passive degradation assessment
To assess degradation of electrocompacted collagen in vitro an assay based on polymer dry
weight was performed (n = 3). The electrocompacted collagen samples were prepared as
described in 2.1.3 and 2.1.4. Next, the samples were incubated in culture medium with standard
culture conditions. The constructs were frozen at -80 °C and subsequently freeze dried overnight
using an ALPHA 2-4 LDplus (Martin Christ, Osterode am Harz, Germany). The dry weight of
the sample was measured at D0, D4, D7 and D14. The degradation was determined through the
equation:

(WT0 – WTx)/ WT0 × 100
Wherein x refers to the specific time point that the weight was measured at and W = dry weight.
Thus, WT0 is the weight pre-degradation and WTx the weight at timepoint x.

2.2 Bioprinting
2.2.1 Cell culture
Rat adrenal medulla PC12 cells were obtained from American Type Culture Collection
(ATCC). PC12 cells were cultured in high-glucose Dulbecco’s Modified Eagle’s Medium
(DMEM) (+L-glutamine, + sodium-pyruvate, + pyridoxine hydrochloride) (Life Technologies,
California, USA), prepared according to manufacturer’s instructions. The medium was
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supplemented with 10% fetal bovine serum (Life Technologies), 5% horse serum (Life
technologies) and 1% Penicillin/Streptomycin (Life Technologies) to produce culture medium
(CM) conditions. PC12 cells were maintained at standard cell culture conditions (humidified
37C, 5% CO2) and passaged 1:4 every 7 days. To differentiate the cells the medium was
changed to high-glucose DMEM supplemented with 1% horse serum (Life Technologies) and
5 ng/mL neural growth factor (NGF), hereafter referred to as differentiation medium (DM)
(Invitrogen, California, USA).

2.2.2 3D printing of polycaprolactone (PCL)
PCL printing was facilitated by a modified BioBots printer (Allevi, Philadelphia, USA). The
extrusion of PCL was pneumatically driven with a pressure of 0.113 MPa. 200 μm nozzle-tips
were used for extruding at a temperature of 119 °C. To prevent the print from dislodging during
the printing process the build plate was heated to approximately 30 °C. Velocity of the printing
was 5 mm/s with a grid infill percentage of 15%. 10x10mm scaffolds of various heights (
ranging from 0.3 to 4 mm) were produced for incorporation of EC collagen. Methacrylated
gelatin (GelMA) bioprinting was attempted with the modified BioBots printer, but failed to print
reliable strands due to temperature variability within the system (n > 5 attempts). As a
consequence, future GelMA printing was done with the 3D Bioplotter (EnvisionTEC, Gladbeck,
Germany).

2.2.3 3D printing of GelMA
GelMA was mixed with its photo initiator, in this case LAP, at 0.05% v/v. Printing of GelMA
constructs was attempted using 10% w/v GelMA. For live cell printing, the cells were
incorporated into the bioink right before loading of the cartridge. Cells were incorporated at a
concentration of 2.0 x 106 cells/mL. To print scaffolds with high fidelity the cartridge was
heated up to 23 °C, while printing occurred at a pressure of 2.5 bar and 6 mm/s. Lastly, the base
plate was cooled to 10 °C.
SolidWorksTM was used to produce cuboidal scaffolds of 10x10 mm as base architecture. The
scaffolds were exported as .stl files and sliced using the RP software for the 3D Bioplotter at
120 um layer slicing. Infill percentages of the cuboids were set to 0° and 90° angles, with 1 mm
distance, and four layers were printed in total. The printed GelMA scaffolds were subsequently
crosslinked for 60 seconds with 365 nm UV-light with a 100 W lamp using a UV LED curing
system (Model no. S1000-1B, Lumen Dynamics, Mississauga, Canada). For live cell printing,
scaffolds containing cells were immediately placed into sterile petri dishes with 1 mL of culture
medium and placed on a 37 °C plate (n = 6).
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2.2.4 Transparency
In order to assess the transparency of the collagen and GelMA samples, light transmission
measurements were performed using a UV-vis spectrophotometer (UV-1800, Shumadzu, Kyoto,
Japan). Non-EC and EC collagen samples (n = 3) were transferred onto a glass-slide and kept in
place by a laser-cut acrylic chamber and cover slip. The same procedure was performed for 5%
and 10% w/v GelMA (n = 3). Deionized water was used as a blank measurement. The
percentage light transmittance (%T) was measured between 400 and 800 nm, as this is
considered within the visible light spectrum.

2.2.5 Metabolic activity measurements using PrestoBlue
To quantify the proliferation of PC12 cells over time, a PrestoBlue cell viability assay was used
(n = 3). PrestoBlue (ThermoFisher, MA, USA) was performed according to manufacturer’s
instructions. PrestoBlue uses a resazurin-based agent that can permeate the cell membrane. The
metabolic activity of cells result in the resazurin being reduced to resorufin, changing the colour
of the solution and this can subsequently be detected using a spectrophotometer. PrestoBlue
samples were taken at constant time intervals at day 0, 3, 5 and 7 for printed and seeded GelMA
scaffolds in culture medium conditions. To take the Prestoblue sample, the scaffolds were
incubated for 1 hour in culture medium conditions supplemented with 20% v/v PrestoBlue
(10x). Next, the medium was aliquoted to a 96-well plate in triplicate and fluorescence was
measured at 544 nm (excitation) and 590 (emission) using a POLARstar Omega microplate
reader (SciQuip Ltd, Shropshire, UK). Cell-free scaffolds were used as negative controls and all
data was analysed according to manufacturer’s protocol.

2.2.6 Live/Dead staining
For certain experiments, cell viability was assessed with Calcein-AM/propidium iodide (PI),
which stain live and dead cells, respectively. Calcein-AM is a cell-permeable esterase substrate,
which is hydrolyzed by esterases present inside living cells. As a result, it is converted into
green fluorescence. PI is an agent which is cell-impermeable, thus cannot stain living cells.
However, upon loss of membrane activity, PI binds to DNA, resulting in a red fluorescence.
Calcein-AM solution (final concentration 10mM) was added to the cells and incubated at
standard cell culture conditions for 10 minutes. Afterwards, PI was added (final concentration 1
μg/ml) and incubated for 5 minutes. Cell viability was assessed at fixed time intervals over the
course of the experiments (n = 3 for every timepoint and experimental condition).
To determine cell viability, the number of living and dead cells were counted using ImageJ
software. In short, all images were converted to 8-bit. Next, the Find Maxima function was used
to count the number of dead or live cells using Point Selection and an acceptable Noise
Tolerance value was determined. The calculation for percentage live cells is as follows:
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Percentage of Live cells = (Live Cells/Live Cells + Dead Cells)x100

2.2.7 Beta-III Tubulin staining
Scaffolds were cultured for a fixed amount of days in differentiation medium with cells, either
seeded or encapsulated, and stained with Beta-III Tubulin in order to visualize the
differentiation of PC12 cells. The constructs were fixed for 1 hour in 4% paraformaldehyde
(Life Technologies). Subsequently, the constructs were washed three times with phosphatebuffered saline (PBS) and permeabilized with 100 ul Methanol: Acetone (50:50) on ice for 5
minutes. Afterwards, constructs were washed with PBS twice and blocked with 10% donkey
serum with 0.1% w/v Tween-20 in PBS, referred to as blocking solution, for 1 hour. Next, the
construct was incubated with mouse anti-Beta III Tubulin, the primary antibody, (COVANCE,
New Jersey, USA) diluted 1:1000 in blocking solution at 4 °C O/N. The construct were washed
with PBS twice and incubated with a secondary antibody, Alexa Fluo546 anti-mouse
(INVITROGEN, California, USA) diluted 1:1000 in blocking solution at 37 °C for 1 hour.
Lastly, constructs were washed with PBS three times, and during the second washing stained
with DAPI (1:1000 in PBS) for 5 minutes at room temperature (RT). All microscope images
were taken with the Zeiss AxioImager A1m or the Zeiss Axiovert 40 CSL (Zeiss, Oberkochen,
Germany).

2.3 Neural Growth Factor incorporation
2.3.1 Microparticle fabrication for NGF release
To have a controlled release of NGF for directed differentiation of PC12 cells microparticles
containing growth factor were fabricated. Polylactic Co-Glycolic acid (PLGA) was chosen as
the base material, as it is a biocompatible and biodegradable co-polymer widely used for
controlled release studies. To synthesize NGF-containing microparticles, a water-in-oil-in-water
(w/o/w) protocol was followed, as already described in72, with adaptations. 200 mg PLGA
(75:25) was dissolved in 1 mL dichloromethane (DCM). The first emulsion was created by
adding 50 ul of DI H2O with varying concentrations of NGF (1 ug, 5 ug and 40 ug) into the
DCM and emulsifying it for 1 minute. This water-in-oil emulsion was subsequently poured into
2 mL of 1% Poly Vinyl Acetate (PVA) and emulsified again for 1 minute. The water-in-oil-inwater emulsion was then poured into 100 mL 1% PVA and after 1 minute of mixing using a
magnetic stirrer 100 mL 2% isopropanol was added. After allowing for solidification of the
microparticles and solvent evaporation the microparticles were washed with DI water thrice and
freeze-dried until further use.
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2.3.2 NGF concentration measurements
To measure unknown concentrations of rat Nerve Growth Factor (NGF) a sandwich ELISA
(R&D Systems, Minnesota, US) was used according to manufacturer’s protocol (n = 3). In
short, samples containing NGF were incubated in PBS at 37 °C and aliquots were taken and
replaced with fresh PBS at regular time intervals for the duration of 8 days. A 96-well plate was
coated with Capture Antibody and incubated overnight at room temperature. Next, the wells
were rinsed with Wash Buffer three times, and blocked with Reagent Diluent for a minimum of
1 hour. After another washing step the obtained samples and standard concentrations were
added and incubated for 2 hours at RT. The washing step was repeated after which a detection
antibody was added and incubated for 2 hours before performing another round of washing
steps. Lastly, Streptavidin-HRP was added to each well, rinsed out with another washing cycle,
and substrate solution was added to each well for 20 minutes before the addition of Stop
solution. The wells were immediately analysed using a POLARstar Omega microplate reader
(SciQuip Ltd, Shropshire, UK) set to determine the optical density at 540 nm and 570 nm. A
standard curve was produced according to manufacturer’s instructions, and the concentration of
unknown samples was measured using this.

2.3.3 Microparticle characterization
To establish correct encapsulation of growth factors with the previously described microparticle
fabrication method FITC-labelled BSA was used as a tracking dye. The fluorescence in the
microparticles was checked with the Zeiss AxioImager A1m or the Zeiss Axiovert 40 CSL.
To establish microparticle size distribution microparticles are imaged after fabrication in 5ul DI
Water on a glass coverslip. Different brightfield images were taken of the microparticles with a
Zeiss Axiovert 40 CFC Microscope (Carl Zeiss, Jena, Germany). The images were analysed
using NIH ImageJ Software. In brief, the original image is converted to a binarized image, after
which the particles are counted and evaluated based on pixel scaling (suppl. Fig. 3). A minimum
of 500 particles were evaluated to generate a reliable distribution of the average size of the
microparticles.

2.3.4 SEM imaging
To investigate the microstructure of electrocompacted collagen structures with and without
microparticles low vacuum SEM imaging was used (GATAN MonoCL4 system, California,
US). Electrompacted collagen sheets were prepared as described in 2.1 and 2.2. To prepare the
samples for SEM imaging a dehydration series was performed (10 mins DI H2O, 10 mins 50%
ethanol, 10 mins 75%, 10 mins 90%, 10 mins 100%, 30 mins HHDS). Afterwards, the samples
(n = 2) were coated with gold to to enable them to be used for SEM imaging.
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2.3.5 In vitro cell study with microparticles
To assess the effect of NGF-loaded microparticles on cell differentiation PC12 cells were plated
out with different culture conditions. The cells used for in vitro differentiation with NGF-loaded
microparticles were kept in culture under standard conditions as described in 2.6 until start of
the experiment. PC12 cells were plated out in 12-well plates at a density of 2 x 104 cells/cm2. At
fixed time intervals bright field images were taken to check for differentiated cells. For the
microparticle experimental groups, the microparticles were weighed and placed inside an
Eppendorf tube with DMEM (+1% Penicillin/Streptomycin, + 1% Horse Serum) (n = 3). Every
other day the DMEM was removed and placed inside the 12-well plate, and fresh medium was
placed inside the Eppendorf tube. This method was chosen as putting the microparticles directly
into the medium inside the well plates would have increased the aspiration of the microparticles
present while changing medium.

2.4 Interfacing
To create a complete innervated model of the cornea ECC and GelMA were interfaced. ECC
was prepared as described in 2.1.1 and GelMA was printed as described in 2.2.3, however for
direct interfacing GelMA was printed onto a steelplate within a petridish to allow for direct EC
on top of the GelMA scaffold. The effect of interfacing was determined through Live/Dead
stainings as described in 2.2.6.

2.5 Statistical analysis
All data were statistically analyzed using SPSS 13.0 (SPSS, Illinois, US) and Prism 7
(GraphPad Software, California, US). P < 0.05 was considered statistically significant.
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Chapter 3: Results and discussion
3.0 Material selection
To create an in vitro model for the cornea, specifically focusing on innervation, various points
need to be taken into consideration. First, it is important to note that there is a disparity in the
optimal biomaterial for, on the one hand, mimicking the cornea and, on the other hand,
providing a platform for nerve cell growth and axonal guidance. Both biomaterials have
different requirements in regards to their mechanical, chemical and biological qualities. In
regards to the optimal biomaterial for use as a corneal tissue equivalent, it is of importance that
it has similar mechanical properties as native cornea. Furthermore, transparency of the
biomaterial used should be similar to native cornea. Lastly, another important component is
stability, especially taking into consideration the fact that an in vitro model needs to have
sustained function and that nerve cells need time for axonal outgrowth to occur. The biomaterial
used as a scaffold for nerve cells needs to be optimized to support the viability of neuronal cells
over time, and secondly to sustain differentiation of these cells and encourage neurite
outgrowth. Thus, keeping these features in mind, and to stay in line with similar work
previously done in this lab, it was decided to use electrocompaction of collagen for mimicking
corneal tissue and methacrylated gelatin (GelMA) bioprinting as a scaffold for nerve cells.
GelMA has been used extensively in bioprinting strategies for tissue engineering, because of its
beneficial properties before, during, and after the 3D printing process.73,74 Additionally, it has
been shown to be able to support the growth of a wide variety of cell types.75 See supplemental
fig. 4 for a schematic representation.

3.1 Electrocompacted collagen
3.1.1 Macroscopic analysis of fabrication
As can be seen in Figure 5, successful electrocompaction (EC) of collagen has been achieved.
The successfulness of the compaction is seen through the formation of a thin sheet-like structure
on the stainless steel plate. The thickness of the formed sheet is between 400 and 800 nm, which
is similar to native cornea.1 Furthermore, through macroscopic analysis it was noted that post
electrocompaction cross-linking with 1mM Riboflavin improved the mechanical strength of the
collagen sheet, as it is able to hold its shape while being clamped (Fig. 5B).
The most commonly used collagen for EC is type-I collagen, although some sources used typeII as well, with the voltage and duration of current application varied (3 volts for 45 min, 6 volts
for 15 min or 5 A/cm-2 for 1 hour).62,76,77 It may be evident that for EC to move forward as a
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reliable and reproducible technique, standardization of its protocol is required. To look more
into the actual changes occurring during the process of EC the current against time can be
plotted (Fig. 5C). The usual curve seen when electrocompacting collagen is an initial decline in
current, followed by a small rise, a steep decline and eventual levelling off.
As 𝐼 = 𝑉/𝑅 where I = Current, V = voltage and R = resistance, the decrease and increase in
current is due to the increase and decrease of the resistance of the collagen solution,
respectively. A possible theory for the increase in resistance over time could be that the tight
packing of collagen molecules that occurs during EC results in a dense layer that increases the
relative resistance of the whole solution. Interestingly, the current (and resistance) stay constant
after approx. 150 seconds, suggesting that the electrocompaction process has been completed
quicker than the duration used in previous studies.61, 62 However, this is a limited quantifiable
method, and should at most be used as a relative comparison between different EC trials. Lastly,
a wide variety of factors heavily influence this process, as attested by the fact that using
collagen sourced from a different animal showed unsuccessful compaction in this project (data
not shown). Thus, strong consideration needs to be given to the origin of the collagen
(animal/synthetic), manufacturer, and type of collagen. To investigate the electrocompacted
collagen as a basis for cornea mimicking certain properties need to be defined.

Figure 5: Electrocompaction of collagen. Pre-crosslinked electrocompacted collagen (A). After
Riboflavin crosslinking (B). Representative graph of current over time for electrocompaction of
collagen type I
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3.1.2 Mechanical assessment
To examine the mechanical properties of the electrocompacted collagen post crosslinking
tensile testing was performed. Figure 6A shows an example of a stress strain curve for ECC. We
could not perform tensile testing on non-compacted collagen due to the softness of the material,
hence the n.a. (not applicable) in the figure. The ultimate strain and ultimate stress were 19.3%
and 81.5 kPa, respectively (Fig. 6C). The tensile modulus of ECC was calculated to be 0.89
MPa with a std. error of mean of 0.076 (Fig. 6B) . The Young’s modulus of the ECC was 221.4
kPa with std. erorr of mean of 51.54 . In this study, tensile modulus was measured at the
steepest incline, while Young’s modulus was measured with the slope at the start of the curve.
To note, tensile testing of conventional collagen hydrogel was not able to be performed due to
inability to be clamped correctly in its wet state. However, collagen hydrogels were determined
to have a tensile modulus ranging from 1 to 28 kPa according to Lopez-Garcia et al.78 Thus, it
can clearly be concluded that the process of electrocompaction drastically increased the
mechanical properties of the collagen. The native human cornea has been reported to have a
tensile modulus between 3-13 MPa.79 In a different study, the Young’s modulus of the human
cornea was determined to be approx. 290 kPa.80 Thus, the tensile moduli reported in this thesis
converges upon the lower bound of the real tensile modulus of the native cornea, although
currently still at least 3.5 fold lower, and the Young’s modulus of ECC is similar to that of
native cornea. All in all, this show the potential of ECC with riboflavin crosslinking as a viable
option for corneal tissue engineering.

Figure 6: Mechanical assessment of riboflavin crosslinked ECC. A typical stress-strain curve
displayed by tensile testing ECC (A). Tensile modulus (B). Ultimate stress and ultimate strain
(C). All values are displayed in kPa and %. Error bars represent std. error of mean (SEM). (n =
3)
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3.1.3 Transparency
To assess the transparency of the biomaterials used in this project the light transmission spectra
from 400 nm to 800 nm was measured. The light transmission measurements showed that the
electrocompacted collagen samples had high transparency within the visible light spectrum (Fig.
7). The values ranged from 85% at 400 nm to 92% at 800 nm. In the native cornea,
transparency plays a critical role in optimal vision through light image formation. The
previously mentioned values are similar to the values obtained from native cornea transparency
measurements (around 80% at 380nm and more than 90% between 500 nm and 1300 nm17),
thus showing the potential of EC collagen to mimic native cornea.81 Comparing these results to
other methods of crosslinking for ECC in literature, such as genipin and EDC-NHS, it is
suggested that riboflavin crosslinking is at least as good if not superior to these other methods.62
Furthermore, several studies using different biomaterials such as non-compacted collagen and
silk films showed similar transparency.82,83 The light transmission measurements of 5% and
10% w/v methacrylated gelatin showed very high transmittance percentages. The values ranged
from 88% at 400 nm to 97% at 800 nm (Fig. 7). These results taken together show the potential
of using a construct that combines both GelMA and ECC as an in vitro model for the cornea,
while maintaining transparency throughout.

Figure 7: Representative light Transmission spectra from collagen and GelMA samples over the
visible light spectrum. The light transmission spectra of the biomaterials was measured
continously between 390 nm and 800 nm and compared to a baseline of DI H2O. The average of n
= 3 was taken for all samples. ECC = electro compacted collagen post-crosslinking, gelMA =
gelatin methylacrylade

3.1.4 In vitro passive degradation assessment
Bioengineering in vitro models of organs present in the native human body requires certain
considerations, one of these being the long-term stability of the construct. Degradation was
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assessed by means of polymer dry weight after soaking in DMEM for a fixed duration of time.
For this study, it was chosen to aim for a material that would be stable for at least a period of 14
days.
The collagen samples used were electrocompacted at 5 volts for 400 seconds, with post crosslinking with 1 mM riboflavin solution. Figure 8 shows the changes in dry weight of ECC taken
at multiple time points. The dry weight slightly decreased from 6.05 ± 0.21 mg on day 0 to 5.85
± 0.64 mg on day 14. The dry weight of ECC appears to have some level of inter-variability. As
mentioned in 2.3, the graphical representation of the current over time shows slight differences
between samples, this slight difference could result in a slight change in structure of the ECC
and hence in the dry weight. Secondly, the ECC was soaked in DMEM for the duration of this
experiment. The samples thus could have gained additional weight through ions present, hence
the higher dry weight measurement at day 4. Kishore et al. showed that ECC was able to
withstand active degradation with collagenase treatment significantly longer compared to noncompacted collagen. 62 Furthermore, post cross-linking drastically increased the stability of the
collagen. All in all, these results indicate that electrocompacted collagen has sufficient stability
to be used as a cornea-mimicking material in long-term in vitro studies.

Figure 8: Passive degradation assessment of electrocompacted collagen samples by means of
dry polymer weight. Data is presented in mean ± SD (n = 2).
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3.2 Bioprinting
3.2.1 Pilot study – PC12 density optimalisation
To introduce neuronal innervation into the model, PC12 cells were chosen as the appropriate
cell line. Historically this cell line has been used extensively in relation to neuronal models.84,85
As a proof of concept, we showed successful differentiation of PC12 cells on plastic culture
plate substrate. PC12 cells started to show neurite outgrowth from day 1 onwards, and in
subsequent days neurite outgrowth increased in length and abundance (Fig. 9). The microscopic
analysis showed that a non-confluent cell seeding density allowed for neurite outgrowth, while
the difference between 2000 cells/cm2 and 4000 cells/cm2 was minimal. Furthermore, it can be
seen that PC12 cells exhibit the tendency to aggregate and cluster together. This cell behavior
could influence the outgrowth of neurites, due to cells ‘blocking’ each other from growing
neurites. The lower seeding density preference has been taken into account in all subsequent
experiments.

Figure 9: Optimizing differentiation density of PC12 cells on plastic culture substrate. Arrows
indicate extensive neurite outgrowth in the differentiation conditions. Scale bar = 200 um. DM =
Differentiation medium, CM = Culture medium
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3.2.2 Optimalisation bioprinting parameters
Preliminary printing was performed to find the optimal printing parameters for high fidelity
prints. Due to the extensive characterization of GelMA in regards to its rheological properties in
literature it was chosen to not include a confirmation of these studies (i.e. rheological evaluation
of 10% w/v GelMA) in this thesis.86,87 Furthermore, optimalisation of the printing parameters
was relatively straightforward, thus no rheological trouble shooting with printing was needed.
Suppl. Fig. 5 shows the microscopic pictures representing different printing parameters. The
bioprinter was programmed to print the construct directly into a petri dish. After optimizing
steps the final parameters for printing of 10% w/v GelMA (0.06% LAP) were: 6 mm/s printing
speed, 23 °C cartridge temperature and 2.5 bar pressure for extruding. Additionally, the stage
was cooled to 10 °C to aid GelMA in retaining its shape post printing. Finally, the prints were
crosslinked for 60 seconds with 365 nm UV-light. As is expected, slower speed of printing as
well as higher pressure increased the strut diameter. Furthermore, increasing the temperature of
printing led to GelMA being extruded in a more liquid form, resulting in a decrease of printing
fidelity.

3.2.3 Microscopic and Live/dead analysis of 3D printed GelMA
Microscopic pictures of day 1 after printing show cells present in printed and seeded constructs
(Fig. 10). Notably, the PC12 cells still exhibit the tendency to aggregate, and are not uniformly
distributed through the scaffold. The presence of live cells inside the printed structures were
confirmed by a live/dead assay 1 day after printing (Fig. 11). Cell viability 1 day post printing
was 29.9%, which was later optimized in 3.4.2. The relative amount of live cells decreased
compared to cell counts taken post-harvesting from the culture flasks before encapsulation and
printing occurred (as confirmed by trypan blue). Generally, it is known that cell viability is
decreased during the printing process.88 The slightly harsh conditions that the cells undergo
before, during and after the printing procedure can result in cell death. For example, crosslinking with UV-light post printing is required in the use of GelMA as a method of stabilizing
the printed structure. However, this can have detrimental effects on cell viability. Overall, the
aim of this experiment was to confirm alive cells to be present, and although viability should be
optimized in the future, live cells have been confirmed to be present within the scaffolds.
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Figure 10: Microscopic analysis of printed and seeded 10% w/v GelMA scaffolds 1 day post
printing. Printed scaffold (top)). Seeded scaffold (bottom). scale bars = 200 um

Figure 11: Live/dead staining of PC12 cells bioprinted within 10% w/v GelMA 1 day post printing.
Live (left), dead (middle), and merged (right). Calcein AM/PI was used to stain the live (green)
and dead (red) cells, respectively. Scale bar = 200 um
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3.2.4 Metabolic activity of PC12 cells
The metabolic activity of the PC12 cells both in seeded and printed constructs was also
assessed. PrestoBlue samples were taken over a period of 7 days, every other day. Data
is represented in absorbance measured, which relates directly to metabolic activity.
Figure 12 shows a very slight decrease in relative metabolic activity of 11.7% from day
1 to day 7. PrestoBlue assays show solely the total metabolic activity of the cells, which
is a mixture of cell proliferation, cell size, metabolic rate and cell survival. Thus, it is
hard to draw definitive conclusions on the results. It could be that the cells present at the
start were stagnant in regards to proliferation, possibly due to being encapsulated
resulting in a relatively stiff 3D environment. This hypothesis holds some weight
considering the preference of neuronal cells for a soft environment.89 On the other hand,
it could be that the rate of cell proliferation and cell death are similar, resulting in a
similar metabolic activity over time. In either case, the presence of living cells was
confirmed in the printed scaffolds for the whole duration of the experiment.
The seeded scaffolds showed a surprising significant decrease of metabolic activity
within 7 days, with a 65.8% reduction in metabolic activity compared to day 1 (p<0.05).
PC12 cells adhere lightly to uncoated substrates, including plastic culture flasks, as
demonstrated by the lack of trypsin needed for passaging of these cells. Thus, constant
medium changing could have dislodged cells partly from the scaffold, and as a result
lowered the overall metabolic activity. This could be confirmed in future studies by
measuring the metabolic activity of the surrounding medium to account for dislodged
cells. To note, the cluster formation present with PC12 cells could influence nutrient
diffusion to cells located in the center of the cluster, thus decreasing overall metabolic
activity.
In future studies, it could be interesting to look at different w/v concentrations of
GelMA and the effect of the softer environment on the encapsulated cells. To note,
lower concentrations of solely GelMA are often incompatible with extrusion-based
printing methods due to insufficient shape retention.90 Thus, these studies should
preferably be performed with molded scaffolds, rather than printed, and therefore will
not be able to be directly compared to the previous data. Together, these data resulted in
advancing the project with PC12 cell printed scaffolds as these showed a sustained
metabolic activity of the cells. Additionally, encapsulation of cells inside the scaffold
mimics native corneal tissue more closely, as the cell bodies providing the free nerve
endings in the native corneal tissue are situated independently of the cornea, where only
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the neurites are protruding into the cornea.91

*
Figure 12: The effect of printing and seeding PC12 cells on their metabolic activity for the
duration of 7 days measured via PrestoBlue. (n = 3) * = P<0.05

3.2.5 Differentiation capacity bioprinted PC12 cells
To assess the differentiation capacity of bioprinted PC12 cells within 10% w/v GelMA scaffolds
cells were stained with Beta-III Tubulin, which is specifically localized in neurons. The cells
were kept in differentiation medium for 12 days before staining, refreshing the medium every
other day. As can be seen in Figure 13, PC12 cells were able to have some level of neurite
outgrowth. It can be seen that outgrowth of neurites is relatively limited compared to the multidirectional outgrowth as seen on 2D plastic substrates (see 3.8.1). In 2D, the neurites are able to
freely spread outwards (not inhibited by a surrounding hydrogel). However, this is not
representative of the native 3D environment. The relatively dense 3D network of GelMA can
hinder new neurite outgrowth from occurring.
Interestingly, the neurites seemed to be topographically guided to extend along the printed
struts. However, for the incorporation of bioprinted neuronal cells into a in vitro model of the
cornea it is required to have guidance cues towards the ECC. Although the topographical cues
from the printed scaffold allow for a semi x/y-directional guidance of neurite outgrowth, to
sustain z-directional outgrowth a different technique is required. Recently, it has been shown
that a NGF concentration gradient can guide neurite outgrowth in PC12 cells within a p(HEMA)
hydrogel.92 Thus, a method for sustained release of NGF from the electrocompacted collagen
was investigated for the progress of this research project.
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Figure 13: Beta-III tubulin staining of PC12 cells printed within 10% w/v GelMA after 12 days.
Neurite outgrowth can be seen going along the printed scaffold. Beta-III Tubulin is displayed in
red and DAPI staining is displayed in blue. Scale bars = 200 um

3.3 Microparticle fabrication
3.3.1 Microparticle characterization
To produce a directionally guided neurite outgrowth model, microparticles were used to provide
for a sustained release of neural growth factor (NGF). The chosen material for these
microparticles was Poly-Lactic Co-glycolic Acid (PLGA), a widely used co-polymer that is
biodegradable and biocompatible.93 To fabricate microparticles loaded with NGF a Water-inoil-in-water (w/o/w) emulsion protocol was followed, adapted to the available lab equipment.
As a proof-of-concept, microparticles loaded with FITC-BSA, a fluorescent protein, were
fabricated using different experimental conditions. This technique resulted in spherical
microparticles with FITC-BSA loaded inside, as confirmed by fluorescent microscopy (Fig. 14).
The fluorescence is limited to the volume inside the microparticles, thus showing successful
encapsulation.

Furthermore, we investigated the effect of PVA concentration and/or PLGA concentration on
the characteristics of the microparticles, focusing on the size of the particles. Histograms of the
size distributions for the different conditions can be found in Figure 15. The smallest average
microparticles size was 20.10 um , using a concentration of 20% PLGA and 1% PVA (Table 1).
Decreasing the PVA concentration, and/or decreasing/increasing the PLGA concentration led to
microparticles with a larger size or larger standard error. Additionally, an increased precipitation
was found when increasing the PLGA concentration to 25%. Therefore, for future use it was
chosen to continue using the 20% PLGA 1% PVA microparticles.

41

Figure 14: Representative fluorescent microscopy pictures of w/o/w PLGA microparticles in
aqueous solution at low (left) and high (right) magnification showing the spherical morphology
and successful encapsulation of FITC-BSA within the microparticles. Scale bars = 200 um

Figure 15: Size distribution by fraction of growth factor loaded PLGA microparticles sized using
ImageJ software. 0.5% PVA, 10% PLGA (A). 1% PVA, 20% PLGA (B). 0.5% PVA, 20% PLGA
(C). 1% PVA, 25% PLGA (D).
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Table 1: Average sizes of the microparticles produced with different concentrations of PVA and
PLGA. All values are represented as mean with std. error of mean

Microparticle fabrication

0.5% PVA

0.5% PVA

1% PVA

1% PVA

method

10% PLGA

20% PLGA

20% PLGA

25% PLGA

Mean size (um)

23.96 ± 0.59

22.21 ± 0.84

20.10 ± 0.60

24.47 ± 0.97

3.3.2 Release studies of NGF microparticles
To assess the growth factor release profile of the optimal particle formulation, an in vitro release
study was performed in PBS at 37 °C using ELISA (fig. 16). For each group, 5 mg of NGFloaded microparticles (NGF:MP) was used to measure the amount of NGF released for 8 days.
Two different loading concentrations were measured: 5 ug and 1 ug loading (per 200 mg
PLGA). During the first 6 hours a fast release can be seen, with 16.80% and 22.56% of the total
NGF released in the 5 ug and 1 ug loaded groups, respectively. After 24 hours the relative NGF
released was 31.8% for 5 ug loading and 54.1% for 1 ug loading. This spiked release leveled off
over the course of 24 hours after which a steady state release was observed for the remainder.
The total amount of NGF released after 8 days was 1.8 ng for 5 ug loading and 0.74 ng for the
1 ug loading group. The initial high burst release of NGF can be explained by the growth
facgtor not being completely encapsulated within the microparticles, but rather being located
near/ bound to the surface of the microparticles. Important to note, the encapsulation efficiency
reached with these experiments is rather low, 5.6% and 1.97% for 1 ug and 5 ug loading,
respectively. Previous work in the institute proved troublesome to encapsulate NGF and
maintain bioactivity. For future studies, it would be important to optimize the encapsulation
efficiency of the microparticles. To summarize, encapsulation of NGF within PLGA
microparticles has been proven, and sustained release has been confirmed.

3.3.3 Ìn vitro cell assay NGF microparticles
To investigate the bioactivity of the NGF:MP, it is necessary to prove their capability to
differentiate neuronal PC12 cells in vitro. To this extent, aliquots of high-glucose DMEM (+1%
P/S, +1% HS) with NGF eluted by 15 mg of 1 ug loaded MPs and 15 mg of 5 ug loaded MPs
were added to PC12 cells every other day. As a negative control empty microparticles were used
together with DMEM (+1% P/S, +1% HS). As expected, PC12 cells cultured in differentiation
medium showed long protruding neurites on day 9. Furthermore, the change of morphology
from rounded cells towards a more neuronal lineage is clearly visible at day 5, as well as some
initial small neurite outgrowth. 5 ug NGF:MP showed signs of differentiation after 9 days in
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culture, with some small neurite outgrowth and a change of morphology in a vast number of
cells (see black arrows). 1 ug NGF:MP showed very little signs of differentiation, with rare
occurrences of morphological changes, even after 9 days. The NGF released from the MPs show
sufficient bioactivity for changing the morphology of PC12 cells towards a more differentiated
lineage. Nevertheless, it is not to an extent that is seen in the positive control. As the end goal is
to use the microparticles in an innervated model wherein neurite outgrowth has to be directed,
the current capacity of differentiation was deemed insufficient. To reach an appropriate amount
of NGF release, future investigations used an increased loading concentration (40 ug loading per
200 mg PLGA).

Figure 16: Release curve showing the absolute cumulative release of neural growth factor from the
0.5% PVA 20% PLGA microparticles over a period of 8 days. Growth factor release was
quantified using ELISA through generating a standard curve (top left) and fitting the unknown data
points after subtracting background absorbance. All measurements were taken in triplicate.

44

Figure 17: Optical microscopic pictures displayed the behavior of the PC12 cells after culturing
with or without NGF:MPs and empty control microparticles for the duration of 9 days. Black
arrows indicate morphological changes and neurite outgrowth. Black dots are microparticles
present in the medium. The positive control shows clear neurite outgrowth from the PC12 cells,
with increasing length from day 5 to day 9. The negative control shows no neurite outgrowth at all
after 9 days, consistent with conventional morphological presence of PC12 cells not stimulated by
NGF. Microparticles loaded with 5 ug (5 ug NGF:MP) can induce neurite outgrowth after 9 days,
but not to the same extent as differentiation medium. Microparticles loaded with 1 ug (1ug
NGF:MP) induce very scarce neurite outgrowth from PC12 cells. Scale bars = 200 um
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3.3.5 Incorporation of microparticles into ECC
After establishing the ability of the MPs to sustain the release of NGF, efforts were undertaken
to incorporate them into the electrocompacted collagen (ECC). This would allow the NGF to be
released in a sustained manner from the cornea-mimicking structure (ie. the ECC), ultimately
guiding the neurite outgrowth towards this structure. Firstly, the ratio of microparticles:collagen
was investigated. A balance has to be found between large amounts of microparticles being
incorporated for maximum release of growth factors, while maintaining the beneficial
mechanical properties of the electrocompacted collagen layer. Three different concentrations of
microparticles/mL of collagen were investigated: 2 mg/mL, 5 mg/mL, and 10 mg/mL.
Macroscopic analysis indicated that 2 mg/mL and 5 mg/mL did not affect the strength of the
electrocompacted collagen sheet compared to the negative control while 10 mg/mL seemed to
affect the formation of a dense sheet of collagen. Scanning Electron Microscopy (SEM) was
used to further examine the structural changes that occurred during EC. Fig. 18A shows ECC
without incorporation of MPs, the aligned collagen fibril structure characteristic for ECC can be
seen by the parallel grooves present. The MPs seem to disrupt the alignment of the collagen
fibers, particularly in higher concentrations. Fig. 18E shows a high magnification image of the
disruption of the smooth surface of the ECC due to microparticle incorporation. These results
show the potential of providing a sustained release of NGF through incorporation of MPs inside
ECC (NGF:MP:ECC).
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Figure 18: Representative scanning electron microscopy (SEM) images of electrocompacted
collagen without microparticles (A), with 5 mg/mL microparticles (B) and 10 mg/mL
microparticles (C, D). (E) shows the disruption of ECC due to microparticle incorporation. Scale
bars as indicated.
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3.4 Innervated model
3.4.1 Interfacing EC and GelMA
To combine both techniques and biomaterials into one single construct multiple avenues of
interfacing have been explored. Logically, there are three different options to explore:
(i) Electrocompaction of collagen into a pre-existing 3D printed GelMA scaffold.
(ii) 3D print a scaffold into pre-electrocompacted collagen.
(iii) Fabricate both constructs separately.

For the first option, one of the integration approaches that can be taken is printing the GelMA
scaffold onto the stainless steel plate, after which the EC chamber can be built around the
scaffold and subsequently the collagen solution can be loaded into and compacted directly on
top of the GelMA (Suppl. Fig. 6). Preliminary testing using a strong and rigid polycaprolactone
(PCL) scaffold, showed potential. The porosity and height of the scaffold was important for the
quality of electrocompaction. Due to this, it was chosen to print 3 layers of GelMA (160
um/layer) with 1.5 mm spacing between strands. A Live/Dead staining was performed to assess
the effect of electrocompaction on cell viability. To identify whether cell death occurs due to
application of an electrical current or the protocol in general (i.e. printing onto a stainless steel
plate and lack of nutrients), another experimental group was added with the same procedure
except for the application of an electrical current. Figure 19 shows the live/dead staining for the
various experimental groups. Cells located on the inside of the scaffold did not survive the
process of electrocompaction, as displayed by 7.8% cell viability (Fig. 19A). However, cells
encapsulated in the outside of the scaffold seemed to have a higher chance of survival, with a
cell viability of 62.45% (fig. 19B). The procedure without electrical current also resulted in
slightly lower cell viability compared to complete control (66.1% and 74.9%, respectively).
Thus, this interfacing approach does not seem optimal. Furthermore, one of the advantages of
printing compared to casting is to allow for relatively rapid nutrient diffusion throughout the
scaffold due to macroscopic porosity. By compacting collagen into the scaffold this advantage is
neutralized, as the pores are filled by the collagen solution. These results taken together show
that this option is unfavorable for the aim of this project.
The second potential approach has not been explored experimentally. Firstly, the surface of
ECC is not completely flat, which makes it difficult to print on. Secondly, the current protocol
requires keeping the printed cells in expansion medium for 24 hours, as they are quite fragile
after the printing procedure. This would not be possible with this option, as the ECC-MP will
elute NGF from day 0 onwards. All taken together, this option was deemed not optimal and thus
option (iii), fabricating both components separately, was currently used for the creation of the
innervated model.
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Figure 19: Live/Dead stainings of PC12 cells within 10% w/v GelMA. (A) middle of scaffold after
electrocompaction of collagen. (B) Top of scaffold after electrocompaction of collagen. (C)
Middle of the scaffold after undergoing the procedure without applying current. (D) control
scaffold. Calcein/PI was used to stain alive (green) and dead (red) cells, respectively. Scale bars =
200 um

3.4.2 Neuronal guidance within interfaced innervated model
To reiterate, the innervated in vitro corneal model was fabricated by combining both
biomaterials post-fabrication. First, to show the optimizing of the printing parameters for cell
viability compared to the first print a live/dead staining was done 24 hours and 7 days after
printing. As can be seen in Figure 20, 24 hours after printing cell viability was 82.4%. It should
be taken into account that before printing viability was 92% as calculated by Trypan Blue. Thus,
a decrease in viability of less than 10% due to printing is better compared to previously in 3.8.2.

NGF:MP:ECC did not show sufficient differentiation for encapsulated PC12 cells within a 10%
w/v GelMA scaffold (Fig. 21). Thus, for the overall model currently the differentiation capacity
of the PC12 cells after printing was insufficient after culturing for 7 days. The positive control
(bioprinted PC12 cells with standard differentiation medium) showed some neurite outgrowth,
indicating differentiation, (Fig. 21A, B). To investigate the cause of this issue, two more
conditions were tested. First, a 10% w/v GelMA 3D printed scaffold seeded with PC12 cells
was analysed to investigate whether the PC12 cells were able to differentiate with GelMA as a
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substrate. This showed more extensive neurite outgrowth (Fig. 21 E, F). Cells can clearly be
seen to sprout multiple neurites in all directions. Thus, clusters of PC12 cells are able to
differentiate when seeded on top of a GelMA scaffold. Secondly, PC12 cells were seeded on
NGF:MP:ECC to assess whether the NGF released from incorporated microparticles was
sufficient for differentiation. The PC12 cells show extensive neurite outgrowth and
differentiation (Fig. 21 G, H). This indicates that the primary cause for the lack of
differentiation in the complete model is the encapsulation within a relative rigid hydrogel.
In literature, differentiation of neuronal cells occurred primarily in collagen-based
hydrogels.96,97 Research within this institute initiated investigations on modified gellan gum
with PC12 cells, which proved relatively unsuccessful, as gellan gum based hydrogels were not
able to show extensive differentiation of PC12 cells.98 Thus, the presence of a soft collagen
hydrogel seems critical to differentiation of PC12 cells. For future investigations, a co-axial setup could be used to fabricate constructs with an inner core of collagen, providing neuronal
support, and an outer shell of GelMA, providing structural support.

Figure 20: Live/Dead staining’s of PC12 cells within 10% w/v GelMA after optimizing the effect
of printing on cell viability after 1 day (left) and 7 days (right). Scale bars = 200 um
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Figure 21: Beta-III tubulin staining of PC12 cells within the interfaced innervated model. Cells
outgrow few neurites when NGF is dispersed within the medium (A, B). No sign of neurite
outgrowth present in the interfaced innervated model of ECC:MP with 10% w/v GelMA (C, D).
Neurite outgrowth can be seen extensively when seeded on top of 10% w/v GelMA (E, F), or
when cultured with NGF:MP:ECC (G, H) . Beta-III Tubulin is displayed in red and DAPI staining is
displayed in blue. Scale bars = 200 um
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3.5 Conclusion and future perspectives
This project aimed to create an in vitro innervated model of the cornea. For this purpose,
electrocompacted collagen was investigated as a basis for corneal mimicking. By examining the
process of electrocompaction we showed the creation of a dense layer of collagen, with similar
thickness to the cornea, and recapitulating partly the unique structure of dense, aligned collagen
lamellae found in the cornea. Furthermore, the mechanical properties of ECC was significantly
better than previously reported mechanical analyses for conventional collagen hydrogels
(P<0.05), and was converging on the mechanical properties for native cornea. The high
transparency of the material and the slow passive degradation in vitro added to the qualities of
this material for use in in vitro cornea models.
The bioprinting of neuronal PC12 cells has been shown for the first time. Cell viability, printing
parameters and seeding density were optimized to achieve adequate scaffolds for PC12 cell
survival 1 day and 7 days post printing. Additionally, to create a guided innervated model,
microparticles were investigated for a sustained release of NGF. Successful encapsulation of
growth factor, sustained release of NGF and 2D PC12 cell response has been achieved. Next,
these microparticles were incorporated into the ECC for guidance of neurite outgrowth into the
cornea mimicking structure. However, although 10% w/v GelMA has been shown to sustain
PC12 survival, it did not allow for sufficient cell differentiation after encapsulation. Adapting or
changing this biomaterial to allow for PC12 differentiation is critical for further progression
(e.g. addition of collagen through a co-axial system).
The successful differentiation of PC12 cells with NGF:MP:ECC has potential for a variety of
applications outside this project. The fabrication of growth factor incorporated microparticles
has been established for a wide variety of growth factors, including VEGF and BMP-2.94,95
Combining a dense collagen sheet with growth factor releasing properties could have potential
for other tissue engineering related strategies as well, whereby the relatively strong and stable
collagen scaffold can provide a platform for promoting vascular or neuronal growth both in
vitro and possibly in vivo due to the incorporation of a method for sustained release. To note,
high concentrations of MPs could influence the strength of the ECC, and future investigations
into quantifying this effect are recommended.
Possibilities for future directions and optimizing within the scope of this project have been
given throughout this thesis, but looking further ahead some exciting directions could be
explored. The additional of other corneal relevant cell types would add immensely to the
relevance of the model as a whole. Cell types including corneal epithelial and endothelial cells
could be added through seeding on the electrocompacted collagen. It has been proposed that
corneal nerves directly innervate corneal cells (including keratocytes), and thus the interaction
between these cell types could be critical to cell behavior. Pre-clinical applications come into
scope if these cells are added successfully. Useful applications such as ocular toxicity testing,
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disease modelling, and permeation studies show that the development of representative 3D in
vitro corneal models remains a priority in the field.
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ABSTRACT
Introduction: Epilepsy is a chronic brain disease characterized by unprovoked seizures, which
can have severe consequences including loss of consciousness and death. Currently, 30% of
epileptic patients do not receive adequate seizure alleviation from oral routes of medication,
despite many new medications becoming available over the last 20 years. A range of
mechanisms have been postulated to account for this, including peripheral metabolism of the
agents, poor absorption, and difficulty traversing the blood-brain barrier. Over the last decade,
local drug delivery to the focal area of the brain where the seizure originates has emerged as a
potential alternative, and may be achieved through the fabrication of drug-loaded polymeric
implants for controlled on-site delivery. The emergence of novel advanced fabrication
techniques has led to potential avenues to further augment implant-based drug delivery systems,
particularly for epilepsy treatment.
Areas covered: This review presents an overview of the latest advanced fabrication techniques
for controlled drug delivery systems for refractory epilepsy treatment. Recent advances in the
different techniques are highlighted and the limitations of the respective techniques are
discussed.
Expert opinion: Advances in biofabrication technologies are expected to enable a new paradigm
of local drug delivery systems through offering high versatility in controlling drug release
profiles, personalized customization and multi-drug incorporation. Tackling some of the current
issues with advanced fabrication methods, including adhering to GMP-standards and industrial
scale-up, together with innovative solutions for complex designs will see to the maturation of
these techniques and result in increased clinical research into implant-based epilepsy treatment.
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Other Supplementary Materials

A

B

C

D

Supplemental figure 1: Complete set-up of the chamber used for electrocompaction of collagen.
(A) ITO-coated glass, (B) non-conducive spacer (C) Stainless steel plate (D) Clamps

Supplemental figure 2: Example of a Stress strain curve conventionally obtained by tensile testing.

63

Supplemental figure 3: Sequential steps of microparticle size characterization. (Top left)
Microscopic image in 16 bit image.; (Top right) Binarized image of microscopic image.; (Bottom
right) Particle counting, removal of irregularities and evaluation of the diameter of the
microparticles based on scaling of pixels .; (Bottom left) Example of histogram generated through
this method of particle counting. ImageJ software was used for all steps.

\
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Supplemental figure 4: schematic representation of full set-up of the proposed innervated corneal
model.
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Supplemental figure 5: Optimalisation steps of printing parameters (Pressure, temperature, and
speed) for 10% w/v GelMA with the Bioplotter. (A) 3.5 bar – 25C – 5 mm/s (B) 3.2 bar – 24C – 6
mm/s (C) 3.0 bar – 25C – 6 mm/s (D) 2.5 bar – 25C – 5 mm/s (E) 3.0 bar – 23C – 6 mm/s

Supplemental figure 6: Direct electrcompaction onto a preprinted PCL scaffold through
assembling the chamber around the scaffold before injecting the collagen solution.
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Biofabrication double degree statement
According to the Memorandum of Agreement between: Queensland University of Technology,
University of Wollongong, Julius-Maximilians-Universität Würzburg and Utrecht University,
the Biofabrication Double degree master’s program was started.
Students in the programme will be expected to obtain a Master’s degree from one European and
one Australian institution. The student initiates the Biofabrication Mobility Programme in a
Master’s degree at the home institution for two semesters (60 EC in Europe) over one year,
prior to taking up enrolment in another Master’s degree at the overseas participating institution,
hereinafter referred to host institution, for a period of two semesters (60 EC in Europe) over one
year.
Students shall enrol in a Master’s degree at the home institution in accordance with the
Biofabrication Mobility Programme specifications approved jointly by the institutions. Students
will undertake a research project at the host institution in accordance with the project
descriptions provided by each institution (supervisory and infrastructure capacity).

The project undertaken at Utrecht University is currently involved in a pending patent
application, and is therefore not attached as an additional appendix. However, it has
successfully been submitted as part of the fulfillment of the Double Degree Masters of
Biofabrication between UoW and University Utrecht.
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